Predicting Fall Risk in Stroke Patients Using a Machine Learning Model and Multi-Sensor Data
Launched by SEOUL NATIONAL UNIVERSITY HOSPITAL · Apr 17, 2024
Trial Information
Current as of July 24, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new way to predict the risk of falls in patients who have had a stroke. Researchers are using a machine learning model that analyzes signals from various sensors, specifically looking at muscle activity, to help determine whether stroke survivors are at high or low risk for falling. The goal is to create a helpful tool that can assist healthcare providers in preventing falls, which can lead to serious injuries for stroke patients.
To participate in this study, stroke survivors need to be at least 19 years old and have experienced their stroke within the last three months. They should also have some weakness in their legs but be able to understand and follow instructions. Individuals with other serious health issues or cognitive impairments may not be eligible. Participants will undergo assessments using the new technology, and their information will help researchers understand how well this predictive tool works. This study is important because it aims to improve safety for stroke survivors and reduce their risk of falls.
Gender
ALL
Eligibility criteria
- • Stroke Participants
- Inclusion Criteria:
- • 19 years and older
- • the onset of the stroke is less than 3months ago
- • Lower extremity weakness due to stroke (MMT =\< 4 grade)
- • Cognitive ability to follow commands
- Exclusion Criteria:
- • stroke recurrence
- • other neurological abnormalities (e.g. parkinson's disease).
- • severely impaired cognition
- • serious and complex medical conditions(e.g. active cancer)
- • cardiac pacemaker or other implanted electronic system
- • Health Participants
- Inclusion Criteria:
- • 19 years and older
- • Individuals who fully understand the necessity of the study and have voluntarily consented to participate as subjects
- Exclusion Criteria:
- • other neurological abnormalities (e.g. parkinson's disease).
- • severely impaired cognition
- • serious and complex medical conditions(e.g. active cancer)
- • cardiac pacemaker or other implanted electronic system
About Seoul National University Hospital
Seoul National University Hospital (SNUH) is a leading medical institution in South Korea, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent clinical trial sponsor, SNUH integrates cutting-edge scientific inquiry with patient-centered care, facilitating the development of novel therapies and treatment protocols. The hospital boasts a diverse range of specialized departments and a robust infrastructure for conducting clinical studies, ensuring rigorous adherence to ethical standards and regulatory compliance. By fostering collaboration among multidisciplinary teams, SNUH aims to contribute significantly to global medical advancements and improve patient outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Seoul, Jongno, Korea, Republic Of
Patients applied
Trial Officials
Woo Hyung Lee, prof
Principal Investigator
Seoul National University Hospital
Byung-Mo Oh, prof
Study Director
Seoul National University Hospital
Han Gil Seo, prof
Study Director
Seoul National University Hospital
Sung Eun Hyun, prof
Study Director
Seoul National University Hospital
Hyunmi Oh, prof
Study Director
National Traffic Injury Rehabilitation Hospital
Sumin Oh, B.S.
Study Director
National Traffic Injury Rehabilitation Hospital
SO YEON JEON, B.S.
Study Director
Seoul National University Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported